Seres Therapeutics (NASDAQ:MCRB) Announces Earnings Results
Seres Therapeutics (NASDAQ:MCRB) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.03, Fidelity Earnings reports. The firm had revenue of $7.03 million for the quarter, compared to the consensus estimate of $6.69 million.
Shares of NASDAQ MCRB traded up $0.02 during midday trading on Friday, reaching $3.69. 125,300 shares of the stock were exchanged, compared to its average volume of 391,248. The business has a 50-day simple moving average of $3.53 and a two-hundred day simple moving average of $3.63. The company has a market capitalization of $283.85 million, a price-to-earnings ratio of -1.52 and a beta of 1.78. Seres Therapeutics has a 12 month low of $2.02 and a 12 month high of $8.88.
MCRB has been the topic of a number of recent analyst reports. Cowen reissued a “buy” rating on shares of Seres Therapeutics in a research report on Monday. Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. Chardan Capital reissued a “buy” rating on shares of Seres Therapeutics in a research report on Thursday, September 19th. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $10.33.
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Featured Story: What is operating income?
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.